| abstract |
The present invention relates to novel angiogenic-inhibitory compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein: Y is a direct bond or a linker group selected from a group of CH2, NH, NR1, S, SO, SO2, or O; Z is CO, CS, SO, SO2, or C=NH; R1 is H, alkyl, alkenyl,alkynyl, cycloalkyl, aryl, arylalkyl, acyl, alkoxyacyl, aryloxyacyl, or aminoacyl groups; R2 is O, S, or NH; A is one to three cycloalkyl or aryl ring groups, in which any of these ring groups may be connected with other ring through a single bond or fused with at least one other ring, and these ring groups are optionally substituted at one or more positions with alkyl, alkoxy, aryl, aryloxy, arylalkyl, arylalkyloxy, hydroxyl, halogen, trihalomethyl, S(O)R, SO¿2?NRR', SO3R, SR, B(OR)2,PR3, P(O)(OR)2, OP(O)(OR)2, NO2, NRR', OR, CN, C(O)R, NHC(O)R, (CH2)nCO2R, or CONRR', wherein R and R' are each independently selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, arylalkyl, and arylalkyloxy and n is 0-11; and B is alkyl, arylalkyl, or one to three cycloalkyl or aryl ring groups, in which any of ring groups may be connected with other ring through a single bond or fused with at least one other ring; and these alkyl, arylalkyl or ring groups are optionally substituted at one or more positions with aryl, alkoxy, aryloxy, arylalkyl, arylalkyloxy, hydroxyl, halogen, trihalomethyl, S(O)R, SO2NRR', SO3R, SR, B(OR)2, P(O)(OR)2, OP(O)(OR)2, NO2, NRR', OR, CN, C(O)R, NHC(OR)R, (CH2)nCO2R, or CONRR', wherein R and R' are each independently selected from the group consisting of H, alkyl, alkoxy, aryl, aryloxy, arylalkyl, arylalkyl, and arylalkyloxy and n is 0-11, pharmaceutical composition comprising them and their use. |